David A. Siegel Oric Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 58,200 shares of ORIC stock, worth $469,674. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,200

Previous 80,100 27.34%

Holding current value

$469,674

Previous $566,000 5.3%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.52 - $11.9 $164,688 - $260,610	-21,900 Reduced 27.34%	58,200 $596,000
Q2 2024 Aug 14, 2024	BUY	$6.63 - $12.93 $338,130 - $659,430	51,000 Added 175.26%	80,100 $566,000
Q1 2024 May 15, 2024	SELL	$8.04 - $16.03 $20,903 - $41,678	-2,600 Reduced 8.2%	29,100 $400,000
Q4 2023 Feb 14, 2024	BUY	$5.41 - $9.43 $28,132 - $49,036	5,200 Added 19.62%	31,700 $291,000
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $317,625 - $487,199	-52,500 Reduced 66.46%	26,500 $160,000
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $163,845 - $278,040	33,100 Added 72.11%	79,000 $613,000
Q1 2023 May 15, 2023	SELL	$4.26 - $6.75 $41,748 - $66,150	-9,800 Reduced 17.59%	45,900 $261,000
Q4 2022 Feb 14, 2023	SELL	$2.41 - $5.89 $271,332 - $663,131	-112,586 Reduced 66.9%	55,700 $328,000
Q3 2022 Nov 14, 2022	SELL	$3.15 - $5.24 $303,074 - $504,161	-96,214 Reduced 36.38%	168,286 $539,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.07 $423,900 - $1.11 Million	157,000 Added 146.05%	264,500 $1.19 Million
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $488,050 - $1.73 Million	107,500 New	107,500 $574,000

Others Institutions Holding ORIC

# of Institutions

124

Shares Held

66.6M

Call Options Held

7.8K

Put Options Held

700

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $319M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account